JP BE guideline, formulation changes (oral solid)
Guideline for Bioequivalence Studies for Formulation Changes of Oral Solid Dosage Forms
Current edition
March 19, 2020 (English translation)
Current edition
March 19, 2020 (English translation)
About this standard
Sets the tests that show a product stays bioequivalent after the non-active components or composition of an oral solid product change after approval. The tests depend on the level of the change.
Recognition by market
Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts
No market listing is published yet.
Testing requirements that cite it
Open the market page and its pathway pages for the full requirement, protocol and report content
Japan
- Bioequivalence after formulation changes of oral solid productsBioequivalence · Not stated
Related standards: JP guideline for bioequivalence studies of generic products, MHRA comparator product guidance, CPMP/EWP/QWP/1401/98 Rev 1, NMPA Notice 2016 No. 61, Annex 3, FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9, M13A. See all standards.